Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias, including anemia, is an important component in the treatment of lower-risk MDS (LR-MDS), and many agents are being evaluated to better manage these. In the context of higher-risk MDS (HR-MDS), many patients may fail to respond to novel agents and the reasons for these failures are a key topic of discussion in the field.
In this podcast, you will hear from Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, and Valeria Santini, MD, University of Florence, Florence, Italy, as they discuss the management of anemia in LR-MDS and strategies to overcome treatment failure in HR-MDS. This discussion was filmed at the 17thInternational Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
The post MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease appeared first on VJHemOnc.
